

General Information	
Ministerial Decision Type	Miscellaneous
Report Title	Amendment to the Prescribed List as of 1 May 2025
Minister	Social Security
Signatory	Minister
Lead Department	Strategic Policy, Planning and Performance (SP3)
Lead Directorate	Public Policy (SP3)
Ministerial Decision Summary: Public or <a href="#">Absolutely/Qualified</a> Exempt	Public Select if more than one Absolutely/Qualified Exemption.
Date decision made if different to date 'Ministerial Decision Summary' signed.	Select date.
Report and Supplemental Report Details	
Report Author	Senior Policy Officer
Date of Report	27/03/2025
Supplementary Report Title <i>(If applicable)</i>	SD Prescribed list as of 1 May 2025
Supplementary Report Author <i>(If applicable)</i>	Prescribing Advisor
Date of Supplementary Report <i>(If applicable)</i>	15/02/2025
Ministerial Decision Report: Public or <a href="#">Absolutely/Qualified</a> Exempt	Public Select if more than one Absolutely/Qualified Exemption.
Relevant Case/Application/URN <i>(Only complete if making a decision related to an appeal where appropriate or allowed under legislation/case/application)</i>	Insert Relevant Case/Application.
Relevant Proposition Number <i>(Only complete if presenting Comments or if lodging an Amendment)</i>	Insert P. number.
Relevant Scrutiny Report <i>(Only complete if presenting a ministerial response)</i>	Insert S.R. number.
Associated Law(s) and/or Subordinate Legislation	Health Insurance (Jersey) Law 1967
Action required if recommendation agreed	Department to take necessary action.

Resource Implications	There are new financial and/or staffing implications. Analysis suggests these changes will result in additional costs of £30,000 per annum
-----------------------	--

### **Introduction**

Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 1 May 2025.

### **Recommendation**

Other

Only insert text if 'Other' selected above.

The Minister accepted recommendations from the PBAC in respect of the following additions and deletions.

#### **1. Additions**

- Melatonin 1mg, 2mg, 3mg, 4mg, 5mg tablets for children and adolescents aged 6-17 with ADHD-related insomnia
- Hydrocortisone 2.5mg, 5mg tablets for replacement therapy in patients with adrenocortical insufficiency (additional strengths; 10mg strength already on Prescribed List)
- Ibuprofen 200mg orodispersible tablets and Ibuprofen 200mg/5ml oral suspension sugar free – non-steroidal anti-inflammatory for mild/moderate pain
- Morphine sulphate orodispersible tablets 1mg, 2.5mg, 5mg, 10mg, 20mg, 30mg (Actimorph brand) for moderate/severe pain
- Latanoprost 50micrograms/ml / Netarsudil 200micrograms/ml eye drops for previously treated primary open-angle glaucoma or ocular hypertension in adults
- Ciclosporin 1mg/ml eye drops 0.3ml unit dose for severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes

- Estradiol 1mg/progesterone 100mg soft capsules (containing 17 $\beta$  estradiol 1 mg plus micronised progesterone 100 mg) (Bijuve brand) for oestrogen deficiency symptoms in postmenopausal women with intact uterus
- Ospemifene 60mg tablets for moderate to severe symptomatic vulvar and vaginal atrophy [in post-menopausal women who are not candidates for local vaginal oestrogen therapy]
- Estradiol (as Estradiol hemihydrate) 1 mg, Norethisterone acetate 500 microgram, Relugolix 40 mg tablets (Ryeqo brand) for moderate to severe uterine fibroids

## **2. Deletions**

- Sodium fusidate 250mg tablets; Fusidic acid 250mg/5ml oral suspension
- NovoRapid (insulin aspart) FlexTouch 100units/ml solution for injection 3ml pre-filled pens
- Insulatard Innolet (insulin isophane human) 100units/ml suspension for injection 3ml pre-filled disposable device
- Insulatard Penfill (insulin isophane human) 100units/ml suspension for injection 3ml cartridges
- Fluticasone 2mg/2ml nebuliser liquid unit dose vial
- Fluticasone 500micrograms/2ml nebuliser liquid unit dose vial
- Clindamycin 1% alcoholic solution
- FemSeven Sequi patches (Estradiol /Levonorgestrel)
- Paroxetine 10mg/5ml oral suspension sugar free
- Testosterone 50mg/5g gel unit dose sachet
- Acetazolamide 250mg modified-release capsules
- Salazopyrin (sulfasalazine) brand-name discontinued
- Sulfasalazine 500mg suppositories
- Victoza (Liraglutide) 6mg/ml solution for injection 3ml pre-filled disposable devices
- Minocycline 100mg tablets and modified-release capsules

## **Financial impact**

Analysis suggests these changes will result in additional costs of £30,000 per annum